» Articles » PMID: 36341380

Harmonization and Qualification of Intracellular Cytokine Staining to Measure Influenza-specific CD4 T Cell Immunity Within the FLUCOP Consortium

Abstract

Despite the knowledge that cell-mediated immunity (CMI) contributes to the reduction of severe influenza infection, transmission, and disease outcome, the correlates of protection for cell-mediated immunity remain still unclear. Therefore, measuring the magnitude and quality of influenza-specific T cell responses in a harmonized way is of utmost importance to improve characterisation of vaccine-induced immunity across different clinical trials. The present study, conducted as part of the FLUCOP project, describes the development of a consensus protocol for the intracellular cytokine staining (ICS) assay, in order to reduce inter-laboratory variability, and its qualification. In order to develop a consensus protocol, the study was divided into different stages. Firstly, two pilot studies evaluated critical parameters in the analytical (read-outs) and post-analytical (gating strategies and data analysis) methods applied by eight different laboratories within the FLUCOP consortium. The methods were then harmonized by fixing the critical parameters and the subsequent consensus protocol was then qualified by one FLUCOP member. The antigen-specific cell population was defined as polypositive CD4 T cells (i.e. positive for at least two markers among CD40L/IFNγ/IL2/TNFα), which was shown to be the most sensitive and specific read-out. The qualification of this consensus protocol showed that the quantification of polypositive CD4 T cells was precise, linear and accurate, and sensitive with a lower limit of quantification of 0.0335% antigen-specific polypositive CD4 T cells. In conclusion, we provide the description of a harmonized ICS assay, which permits quantitative and qualitative evaluation of influenza vaccine-induced T cell responses. Application of this harmonized assay may allow for future comparisons of T cell responses to different influenza vaccines. It may facilitate future assessments of potential correlates of protection with the promise of application across other pathogens.

Citing Articles

Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK.

Waldock J, Cox R, Chiu C, Subbarao K, Wildfire A, Barclay W Influenza Other Respir Viruses. 2024; 18(11):e70014.

PMID: 39496425 PMC: 11534430. DOI: 10.1111/irv.70014.


Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation.

Lane M, Luke C, Bresee J, Dugan V, Post D, Schafer J Influenza Other Respir Viruses. 2024; 18(10):e13358.

PMID: 39440405 PMC: 11496904. DOI: 10.1111/irv.13358.


Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".

Krammer F, Katz J, Engelhardt O, Post D, Roberts P, Sullivan S Influenza Other Respir Viruses. 2024; 18(10):e13314.

PMID: 39380156 PMC: 11461279. DOI: 10.1111/irv.13314.


Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study.

DOnofrio V, Porrez S, Jacobs B, Alhatemi A, De Boever F, Waerlop G Vaccines (Basel). 2024; 12(9).

PMID: 39340066 PMC: 11435821. DOI: 10.3390/vaccines12091036.


Unravelling influenza correlates of protection: lessons from human A/H1N1 Challenge.

Cox R, Pathirana R mBio. 2024; 15(5):e0006424.

PMID: 38546212 PMC: 11078003. DOI: 10.1128/mbio.00064-24.


References
1.
McNeil L, Price L, Britten C, Jaimes M, Maecker H, Odunsi K . A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2013; 83(8):728-38. PMC: 4443815. DOI: 10.1002/cyto.a.22319. View

2.
Trieu M, Zhou F, Lartey S, Jul-Larsen A, Mjaaland S, Sridhar S . Long-term Maintenance of the Influenza-Specific Cross-Reactive Memory CD4+ T-Cell Responses Following Repeated Annual Influenza Vaccination. J Infect Dis. 2016; 215(5):740-749. DOI: 10.1093/infdis/jiw619. View

3.
Price L, Adamow M, Attig S, Fecci P, Norberg P, Reap E . Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2020; 99(1):107-116. DOI: 10.1002/cyto.a.24244. View

4.
Du L, Grover A, Ramanan S, Litwin V . The evolution of guidelines for the validation of flow cytometric methods. Int J Lab Hematol. 2015; 37 Suppl 1:3-10. DOI: 10.1111/ijlh.12344. View

5.
Paget J, Spreeuwenberg P, Charu V, Taylor R, Iuliano A, Bresee J . Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019; 9(2):020421. PMC: 6815659. DOI: 10.7189/jogh.09.020421. View